Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenerimod in Moderate-to-Severe Systemic Lupus Erythematosus (OPUS-1)
NCT05648500Phase 3Active, not recruiting
- Sponsor
- Viatris
- Start
- Dec 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of cenerimod in systemic lupus erythematosus (SLE), sponsored by Viatris. Started Dec 2022; status: active, not recruiting.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05648500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648500.